Related Experiment Video
Updated: Nov 17, 2025
11:29
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.3K
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review
Philippe Decruyenaere1,2,3, Fritz Offner4, Jo Vandesompele5,6
1Department of Hematology, Ghent University Hospital, 9K12, Campus UZ Ghent, Corneel Heymanslaan 10, 9000, Ghent, Belgium. philippe.decruyenaere@ugent.be.
Experimental Hematology & Oncology
|February 17, 2021
Summary
Circulating RNA molecules show promise as biomarkers for diffuse large B-cell lymphoma (DLBCL), a common non-Hodgkin
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Diffuse large B-cell lymphoma (DLBCL) is the most prevalent non-Hodgkin's lymphoma (NHL), characterized by significant heterogeneity.
- Standard immunochemotherapy achieves remission in most patients, but refractory or relapsed DLBCL after first-line treatment carries a poor prognosis, highlighting an unmet clinical need.
- Advances in understanding DLBCL pathogenesis have spurred the development of novel biomarkers, including cell-free nucleic acids in liquid biopsies.
Purpose of the Study:
- To systematically review and synthesize current knowledge on circulating RNA molecules as biomarkers in DLBCL.
- To evaluate the potential of circulating RNA for diagnosing DLBCL, determining subtypes, predicting treatment response, and prognostication.
- To discuss the future prospects of circulating RNA biomarkers in DLBCL management.
Main Methods:
- A systematic literature search was conducted using PubMed.
- Inclusion criteria focused on studies evaluating circulating RNA (mRNA, miRNA, lncRNA, circRNA) as biomarkers in human DLBCL populations.
- A total of 35 relevant articles were identified and included in the review.
Main Results:
- Growing interest exists in circulating-free RNA and RNA within extracellular vesicles or tumor-educated platelets (TEPs) as biomarkers.
- Studies have explored various circulating RNA types, including messenger RNA (mRNA), microRNA (miRNA), long non-coding RNA (lncRNA), and circular RNA (circRNA).
- Circulating RNA has been investigated for diagnostic, subtype classification, treatment response assessment, and prognostic applications in DLBCL.
Conclusions:
- Circulating RNA molecules represent a promising area for biomarker development in DLBCL.
- Further research is warranted to fully elucidate the diagnostic, prognostic, and predictive potential of these biomarkers.
- Circulating RNA biomarkers could offer new avenues for personalized medicine approaches in DLBCL treatment.
